pentobarbital has been researched along with Long Sleeper Syndrome in 18 studies
Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pentobarbital has been shown to reduce the time to sleep onset, decrease the number of body movements during sleep and spontaneous awakenings and increase the total sleep time." | 5.40 | The use of pentobarbital in cases of severe delirium: a case series. ( Hang, PC; Holahan, T; Kerr, CW; Luczkiewicz, DL; Milch, R, 2014) |
| " The pharmacological properties of goodyerin were assayed for effects on spontaneous locomotor activity, on pentobarbital-induced hypnosis, and on anticonvulsant activity against picrotoxin-induced seizures in rodents." | 3.71 | Sedative and anticonvulsant activities of goodyerin, a flavonol glycoside from Goodyera schlechtendaliana. ( Du, XM; Guo, YT; Shoyama, Y; Sun, NY; Takizawa, N, 2002) |
| "Treatment of sleep disorders promotes the long-term use of commercially available sleep inducers that have several adverse effects, including addiction, systemic fatigue, weakness, loss of concentration, headache, and digestive problems." | 1.72 | Effect of Hibiscus syriacus Linnaeus extract and its active constituent, saponarin, in animal models of stress-induced sleep disturbances and pentobarbital-induced sleep. ( Kim, YR; Lee, MY; Lee, SM; Lee, SY; Shim, I, 2022) |
| "Pentobarbital has been shown to reduce the time to sleep onset, decrease the number of body movements during sleep and spontaneous awakenings and increase the total sleep time." | 1.40 | The use of pentobarbital in cases of severe delirium: a case series. ( Hang, PC; Holahan, T; Kerr, CW; Luczkiewicz, DL; Milch, R, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (61.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YR | 1 |
| Lee, SY | 1 |
| Lee, SM | 1 |
| Shim, I | 1 |
| Lee, MY | 1 |
| Lin, A | 1 |
| Shih, CT | 1 |
| Chu, HF | 1 |
| Chen, CW | 1 |
| Cheng, YT | 1 |
| Wu, CC | 1 |
| Yang, CCH | 1 |
| Tsai, YC | 1 |
| Eikermann, M | 1 |
| Eckert, DJ | 1 |
| Chamberlin, NL | 1 |
| Jordan, AS | 1 |
| Zaremba, S | 1 |
| Smith, S | 1 |
| Rosow, C | 1 |
| Malhotra, A | 1 |
| Egashira, N | 1 |
| Nogami, A | 1 |
| Iwasaki, K | 1 |
| Ishibashi, A | 1 |
| Uchida, N | 1 |
| Takasaki, K | 1 |
| Mishima, K | 1 |
| Nishimura, R | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Kerr, CW | 1 |
| Luczkiewicz, DL | 1 |
| Holahan, T | 1 |
| Milch, R | 1 |
| Hang, PC | 1 |
| Du, XM | 1 |
| Sun, NY | 1 |
| Takizawa, N | 1 |
| Guo, YT | 1 |
| Shoyama, Y | 1 |
| SCHMIDT, R | 1 |
| WALLNER, S | 1 |
| BOEHRINGER, A | 1 |
| ENGELMEIER, MP | 1 |
| Saito, K | 1 |
| Umeda, S | 1 |
| Kawashima, K | 1 |
| Kano, Y | 1 |
| Sechzer, PH | 1 |
| Chapron, DJ | 1 |
| Mumford, D | 1 |
| Pitegoff, GI | 1 |
| Fassolt, A | 1 |
| Hauri, P | 1 |
| Hawkins, DR | 1 |
| Mima, T | 1 |
| Okumura, F | 1 |
| Onji, H | 1 |
| Johns, MW | 1 |
| Hepburn, M | 1 |
| Goodyear, MD | 1 |
| Lechler, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Sevoflurane, Propofol, and Carbon Dioxide 'Reversal' on Upper Airway Collapsibility in Healthy, Adult Subjects[NCT01557920] | Phase 4 | 18 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(T(ins)/T(total))*100 (NCT01557920)
Timeframe: Will be measured before and during anesthesia until emergence from anesthesia, an expected average of 6 hours
| Intervention | percentage of Ttotal (Mean) |
|---|---|
| Wakefulness | 42 |
| Anesthesia With Low Dose Sevoflurane (Baseline CO2) | 42 |
| Anesthesia With High Dose Sevoflurane (Baseline CO2) | 43 |
| Anesthesia With Low Dose Propofol (CO2 Baseline) | 40 |
| Anesthesia With High Dose Propofol (CO2 Baseline) | 41 |
The number of swallows were counted during wakefulness and anesthesia. The frequency of swallowing was calculated per hour (NCT01557920)
Timeframe: swallows were measured during steady state conditions (mean±SEM, 2.6±0.6h)
| Intervention | number of swallows/hr (Mean) |
|---|---|
| Anesthesia With Propofol and Sevoflurane | 1.7 |
| Wakefulness | 28 |
will be measured during steady state anesthesia as well as during carbon dioxide reversal, and during recovery from anesthesia. (NCT01557920)
Timeframe: participants will be followed for the duration of anesthesia until full recovery, an expected average of 9 hours
| Intervention | percentage of maximum recorded activity (Mean) |
|---|---|
| Phasic Genioglossus Activity (Light Anesthesia) | 32.8 |
| Tonic Genioglossus Activity (Light Anesthesia) | 24.2 |
| Phasic Genioglossus Activity (Deep Anesthesia) | 26.0 |
| Tonic Genioglossus Activity (Deep Anesthesia) | 22.3 |
Measured by spirometry. Subjects wear a full-face mask. Reported in L/min (NCT01557920)
Timeframe: Will be measured before and during anesthesia until emergence from anesthesia, an expected average of 6 hours
| Intervention | L/min (Mean) |
|---|---|
| Wakefulness | 7.9 |
| Anesthesia With Low Dose Sevoflurane (Baseline CO2) | 6.7 |
| Anesthesia With High Dose Sevoflurane (Baseline CO2) | 5.6 |
| Anesthesia With Low Dose Propofol (CO2 Baseline) | 7.2 |
| Anesthesia With High Dose Propofol (CO2 Baseline) | 5.7 |
A pathological swallow was defined as a swallow that was followed by inspiratory flow. A physiological swallow was defined as a swallow that was followed by expiratory flow. The number of pathological and physiological swallows were measured during wakefulness and anesthesia. The pathological swallows are presented as percentage of path. swallows calculated as path.sw/[path.sw+phys.sw]*100 (%). (NCT01557920)
Timeframe: swallows were measured during steady state conditions (mean±SEM, 2.6±0.6h)
| Intervention | percentage of pathological swallows (Number) |
|---|---|
| Anesthesia With Propofol and Sevoflurane (All Cases) | 25.9 |
| Wakefulness (All Cases) | 4.9 |
| Anesthesia With Propofol and Sevoflurane (Baseline CO2) | 15.8 |
| Anesthesia With Propofol and Sevoflurane (CO2 Insufflation) | 34.9 |
| Wakefulness (During Baseline CO2) | 1.0 |
| Wakefulness (With CO2 Insufflation) | 13.2 |
Upper airway closing pressure will be measured during steady state anesthesia as well as during carbon dioxide reversal. (NCT01557920)
Timeframe: participants will be followed for the duration of anesthesia, an expected average of 6 hours
| Intervention | cm H20 (Mean) |
|---|---|
| Propofol | -9.83 |
| Sevoflurane | -10.77 |
4 trials available for pentobarbital and Long Sleeper Syndrome
| Article | Year |
|---|---|
Effects of pentobarbital on upper airway patency during sleep.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Electromyography; Female; Humans; Hypnot | 2010 |
Demand method evaluation of hypnotics.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Drug Evaluation; Fem | 1976 |
[The clinical efficiency of some hypnotics in cases of preoperative sleeping disturbances (author's transl)].
Topics: Adult; Clinical Trials as Topic; Diazepam; Drug Combinations; Drug Therapy, Combination; Female; Glu | 1975 |
[Studies on preoperative anxiety and sleep disorders].
Topics: Anxiety; Clinical Trials as Topic; Diazepam; Female; Humans; Male; Pentobarbital; Placebos; Preopera | 1968 |
14 other studies available for pentobarbital and Long Sleeper Syndrome
| Article | Year |
|---|---|
Effect of Hibiscus syriacus Linnaeus extract and its active constituent, saponarin, in animal models of stress-induced sleep disturbances and pentobarbital-induced sleep.
Topics: Animals; Apigenin; Cerebral Cortex; Corticosterone; Disease Models, Animal; Electroencephalography; | 2022 |
Lactobacillus fermentum PS150 promotes non-rapid eye movement sleep in the first night effect of mice.
Topics: Animals; Disease Models, Animal; Gastrointestinal Microbiome; Limosilactobacillus fermentum; Male; M | 2021 |
Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABA(A)-benzodiazepine receptor complex.
Topics: Animals; Bicuculline; Dose-Response Relationship, Drug; Drug Synergism; Drugs, Chinese Herbal; Fluma | 2011 |
The use of pentobarbital in cases of severe delirium: a case series.
Topics: Aged, 80 and over; Delirium; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Palliative | 2014 |
Sedative and anticonvulsant activities of goodyerin, a flavonol glycoside from Goodyera schlechtendaliana.
Topics: Animals; Anticonvulsants; Convulsants; Disaccharides; Flavonoids; Flavonols; Glycosides; Hypnotics a | 2002 |
[On the medical therapy of insomnia].
Topics: Health Services; Humans; Pentobarbital; Sleep Initiation and Maintenance Disorders; Sleep Wake Disor | 1962 |
[EXPERIENCES WITH THE SEDATIVE PENTOBARBITAL CALCIUM (REPOCAL)].
Topics: Calcium, Dietary; Humans; Hypnotics and Sedatives; Liver Diseases; Pentobarbital; Sleep Wake Disorde | 1963 |
[CLINICAL EXPERIENCES WITH PENTOBARBITAL IN A PSYCHIATRIC CLINIC].
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Drug Therapy; Humans; Mental Disorders; Pa | 1964 |
[ON A METHOD OF TESTING HYPNOTIC DRUGS].
Topics: Barbiturates; Biomedical Research; Hypnotics and Sedatives; Mental Disorders; Pentobarbital; Placebo | 1964 |
Pharmacological properties of traditional medicines. XXVI. Effects of Sansohnin-to on pentobarbital sleep in stressed mice.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drugs, Chinese Herbal; Hypnotics and Sedative | 2000 |
Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital: a case of sequential drug interactions.
Topics: Aged; Atrial Fibrillation; Digoxin; Drug Interactions; Female; Half-Life; Humans; Liver; Pentobarbit | 1979 |
Human sleep after leucotomy. A case study.
Topics: Amitriptyline; Chlorpromazine; Depression; Electroencephalography; Female; Frontal Lobe; Humans; Mid | 1972 |
Use of hypnotic drugs by hospital patients.
Topics: Adult; Aged; Amobarbital; Antipyrine; Barbiturates; Diphenhydramine; Female; Hospitalization; Humans | 1971 |
[Clinical experiences with norkotral, a new hypnotic].
Topics: Humans; Hypnotics and Sedatives; Mental Disorders; Pentobarbital; Promazine; Sleep Wake Disorders | 1966 |